Empirical antifungal therapy
- 1 February 2004
- journal article
- review article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 23 (2) , 105-112
- https://doi.org/10.1016/j.ijantimicag.2003.11.002
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- In Vitro Synergy of Caspofungin and Itraconazole against Aspergillus spp.: MIC versus Minimal Effective Concentration End PointsAntimicrobial Agents and Chemotherapy, 2003
- Use of Circulating Galactomannan Screening for Early Diagnosis of Invasive Aspergillosis in Allogeneic Stem Cell Transplant RecipientsThe Journal of Infectious Diseases, 2002
- Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisNew England Journal of Medicine, 2002
- New antifungal agentsSeminars in Respiratory Infections, 2002
- Empirical Antifungal Therapy — New Options, New TradeoffsNew England Journal of Medicine, 2002
- The Direct Cost and Incidence of Systemic Fungal InfectionsValue in Health, 2002
- A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile NeutropeniaClinical Infectious Diseases, 2000
- Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trialEuropean Journal Of Cancer, 1996
- Empiric antifungal therapy in febrile granulocytopenic patientsThe American Journal of Medicine, 1989
- Empiric Antimicrobial Therapy for Febrile Granulocytopenic Cancer Patients: Lessons from four EORTC trialsActa Oncologica, 1988